A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

Condition(s) targeted: Schizophrenia; Diabetes Mellitus

Intervention: risperidone; olanzapine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Janssen, LP

Official(s) and/or principal investigator(s):
LP Clinical Trial Janssen, Study Director, Affiliation: Janssen, LP

The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.

Official title: A Six-Month, Double-Blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder

Study design: Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Change in the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test (which shows how the body regulates glucose) over 6 months.

Secondary outcome:

Changes in measurements of metabolism and glucose regulation

changes in results of tests and questionnaires that evaluate the effectiveness and safety (including laboratory tests and anthropomatic measurements) of medications used to treat schizophrenia.

Detailed description: The newer antipsychotic medications risperidone and olanzapine effectively treat schizophrenia and related disorders, and they may cause fewer side effects than the older antipsychotic drugs do. However, some of the newer antipsychotic medications could have a negative effect on the regulation of blood glucose (sugar) in the body. This negative effect could make the patient gain weight and even develop diabetes mellitus. This randomized, double-blind study will assess and compare how risperidone and olanzapine affect the regulation of glucose in the body in patients with schizophrenia and schizoaffective disorder. Patients will be randomly assigned to receive risperidone (target oral dose of 6 milligrams per day) or olanzapine (target oral dose of 20 milligrams per day) for 6 months. Repeat laboratory measurements will be performed and questions will be asked of the patients to evaluate the safety and effectiveness of the drugs. The primary laboratory test used to assess the patient's regulation of blood glucose will be the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test.

Risperidone 2 milligram oven-encapsulated tablets taken orally once a day for 6 months; olanzapine 5 milligram tablets taken orally once a day for 6 months

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of schizophrenia or related disorder

- Stable with respect to disease symptoms and other medical conditions

- Would benefit from this type of antipsychotic drug

- If female, using birth control

Exclusion Criteria:

- Patients who are delirious, bipolar, severely mentally retarded, or suicidal

- Psychiatric diagnosis of disease unrelated to schizophrenia

- Presence of stroke, brain tumor, Parkinson's Disease, or diseases that affect blood glucose control

- History of diabetes

- Long or recent history of taking risperidone, olanzapine, quetiapine, clozapine, or investigational drugs

- Recent history of unstable thyroid function

- If female, not using birth control

- Abusing drugs or alcohol

A Six-Month, Double Blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects with Schizophrenia or Schizoaffective disorder.

Ending date: August 2003
Last updated: May 11, 2007